
Low-dose naltrexone (LDN) in Hashimoto thyroiditis: mechanism, dosing, protocol
Naltrexone at 1.5–4.5 mg/day (10 times lower than addiction-medicine dosing) ceases to act primarily as an antagonist and becomes an immunomodulator. Short nocturnal blockade of μ-opioid receptors produces a rebound increase in endogenous endorphins, TLR4 blockade on microglia, and a Th17 / Treg shift toward tolerance. In Hashimoto thyroiditis, LDN is a third-line candidate when TPO antibodies remain elevated despite an adequate L-T4 dose and corrected selenium and vitamin D deficiencies. I review the mechanism, titration protocol, expected time to effect, and settings where LDN should not be used.










